Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer

BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors (CDKi) have changed the landscape for treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER−) metastatic breast cancer (MBC). However, next-line treatment strategies after CDKi progression a...

Descripción completa

Detalles Bibliográficos
Autores principales: West, Malinda T, Goodyear, Shaun M, Hobbs, Evthokia A, Kaempf, Andy, Kartika, Thomas, Ribkoff, Jessica, Chun, Brie, Mitri, Zahi I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400146/
https://www.ncbi.nlm.nih.gov/pubmed/36946994
http://dx.doi.org/10.1093/oncolo/oyad035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400146/
https://www.ncbi.nlm.nih.gov/pubmed/36946994
http://dx.doi.org/10.1093/oncolo/oyad035

Ejemplares similares